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ambulatory hospital care in the LTG group (LTG 20 vs. LEV 10). No signiﬁcant dif-
ference was found concerning the self-reported health status of the patients (mean EQ 
VAS at follow-up: LTG 75.2 o 18.1 vs. LEV 74.8 o 24.7) nor depression (mean BDI 
sumscore at follow-up: LTG 7.1 o 5.9 vs. LEV 5.9 o 7.5). CONCLUSIONS: No sig-
niﬁcant differences were detected between the two treatment arms concerning ambula-
tory or stationary resource use, self-reported health status or depression. Non-inferiority 
should be proven with an adequate trial design.
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OBJECTIVES: To assess the cost-utility of rasagiline or entacapone (COMT) as 
adjunctive therapies to levodopa (LD) versus carbidopa/levodopa/entacapone (LCE) 
versus standard LD monotherapy in patients with advanced PD and motor ﬂuctuations 
in the US. As PD progresses, patients and their families experience substantial health 
and economic burdens. Because motor ﬂuctuations are linked to poor quality of life 
and higher health care costs minimizing off-time is an effective strategy for reducing 
costs associated with PD. METHODS: A two-year Markov model was utilized to 
examine the cost-effectiveness of advanced PD treatments. Patients may transition 
therapy every four months. Transition probabilities were obtained from clinical trial 
data. Medical costs, drug costs and utility weights were from published literature. 
RESULTS: Over two years, all therapy options showed greater effectiveness than LD 
alone. Rasagiline and LCE were cost saving from a payer perspective; while COMT 
was cost saving from a societal perspective. Beneﬁts over 2 years were 0.12 additional 
QALYs for rasagiline, COMT and LCE and 5.08 additional months with 25% off-
time for rasagiline and 4.85 for COMT and LCE versus LD alone. CONCLUSIONS: 
From a payer perspective, rasagiline and LCE were dominant therapies to LD mono-
therapy; while COMT was effective at higher cost. With no additional cost over a 2 
year period, rasagiline presents a valuable alternative to COMT, LCE and LD mono-
therapy in the treatment of advanced PD patients. Results from this cost-utility model 
and prior adjunctive clinical data provides ongoing support for rasagiline’s adjunctive 
use in moderate to advanced PD patients with motor ﬂuctuations.
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OBJECTIVES: To assess the cost-effectiveness of memantine, compared with standard 
care, in moderate to severe Alzheimer’s disease (AD) patients. METHODS: A cost-
utility analysis was conducted based on a 3-state Markov model, which simulated 5-
year evolution of pre Full-Time-Care (FTC) patients with and without memantine 
treatment in addition to any background AD therapy, in terms of time-to-FTC, 
Quality-Adjusted-Life-Years (QALYs), and cost. Transition from the pre-FTC to the 
FTC state was modelled using new predictive equations estimating time-to-FTC based 
on clinical assessment of cognition, function, and behaviour. The equations were 
derived from cohort of patients with dementia followed for four years. Treatment 
effect was estimated based on the published meta-analysis of six memantine RCTs. 
Both health utilities (EQ-5D) and resource utilization for the model came from a 
Scandinavian Study of Cost and Quality of Life in AD. Costs were valued from the 
societal perspective, and covered routine patient management, hospitalization, social 
community services, institutionalisation, medications, loss in productivity, and leisure 
time. Memantine cost was accounted for until patients required FTC (conservative). 
Costs and beneﬁts were discounted at an annual rate of 3%. Results were reported in 
Euros (NOK), 2008. The model underwent extensive stochastic and one-way sensitiv-
ity analyses testing the impact of model assumptions and changes in input values for 
treatment effect, health utilities, cost, and discounting rates. RESULTS: Memantine 
was associated with a longer time-to-FTC of 21 days, QALYs gains of 0.02 and a cost 
saving of above a-900 (7,500NOK). Lower costs in memantine group were due to 
prolonged pre-FTC time and offset drug acquisition cost. Memantine was cost-
 effective at a40,000 (300,000NOK) thresholds (72.86%). The sensitivity analyses 
conﬁrmed the robustness of the base-case scenario. CONCLUSIONS: Memantine 
is associated with higher beneﬁts for no additional costs relative to standard care, 
and is a cost-effective treatment.
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OBJECTIVES: Estimate the cost-utility of interferon beta 1B (IFNB-1b) in patients 
with a clinically isolated syndrome (CIS) suggestive of multiple sclerosis (MS). 
METHODS: A Markov model was developed using the epidemiology and treatment 
of CIS and MS. The model simulates outcomes over time horizons ranging from 2 
years to lifetime. A hypothetical cohort of 1,000 patients with incident CIS, with initial 
health states deﬁned by Kurtzke’s Expanded Disability Symptom Scale (EDSS), was 
speciﬁed. The cohort was assumed alternatively to be treated with IFNB-1b (250 mg 
eod) following an initial demyelinating event suggestive of MS or not treated until 
conﬁrmation of MS.Data from study BENEFIT was used to model EDSS progression 
over time and transitions from CIS to MS. Exacerbations (relapses) were estimated 
from BENEFIT and published natural history data. Following transition to MS, all 
patients were assumed to be treated with IFNB-1b until EDSS 6.5. Direct and indirect 
medical costs of MS treatment and IFNB-1b were estimated from published literature 
and pricing schedules. Patient utilities were derived from EQ-5D data , supplemented 
by published data deﬁned by EDSS score and relapse occurrence. Mortality was esti-
mated using life tables and EDSS data. Costs (a2008) and outcomes were discounted 
at 3% per annum. Sensitivity analyses were performed on all key model parameters. 
RESULTS: Use of IFNB-1b was associated with slower EDSS progression (longer time 
to MS diagnosis), and reduced relapse burden. In the base case (50-year time horizon), 
ICUR of IFNB-1b versus no treatment was a20,500 / QALY gained using Poser diag-
nostic criteria and dominates using McDonald diagnostic criteria. Findings were sensi-
tive to simulation time horizon, IFNB-1b cost and treatment effect (underlying rate of 
disease progression). CONCLUSIONS: IFNB-1b—treatment of patients with a CIS 
appears to offer reasonable value for money relative to many well accepted health 
care interventions.
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OBJECTIVES: Medicines must be shown to be both clinically and cost-effective 
compared to alternatives in order to be recommended by the National Health Service. 
This study evaluated the cost-effectiveness of pregabalin compared to usual care, in 
patients with refractory neuropathic pain (NeP), i.e., those who had achieved an 
inadequate response to, or were intolerant of, earlier medication including amitripty-
line and gabapentin. METHODS: A Discrete Event Simulation (DES) model was 
constructed to evaluate clinical and economic outcomes of pregabalin versus usual 
care in patients with refractory NeP. An open-label, long term study evaluating pre-
gabalin’s effectiveness in refractory NeP patients over 15 months was used as the 
clinical input to the model. The ‘usual care’ comparator was deﬁned as a group of 
pain medications comprising weak opioids, strong opioids, NSAIDs and/or analgesics. 
New utility data was collected using the EQ-5D via a UK postal survey of hospital 
patients with refractory NeP. This survey also collected costs of other pain medication 
and other health care resources consumed by patients. In each weekly cycle, patients 
accrued costs and beneﬁts associated with their pain score in that cycle, which was 
uniquely deﬁned by the input clinical data. Adverse events and withdrawals, and their 
cost and disutility, were estimated, also based on the input clinical data. Total costs 
and beneﬁts were summed and extrapolated over the ﬁve-year time horizon of the 
model to calculate the ICER. RESULTS: The base case analysis estimated the ICER 
at £10,803/QALY. One-way sensitivity analyses showed that the ICER was stable to 
changes in all input parameters. CONCLUSIONS: This economic evaluation used 
new, real-world utility data in refractory NeP to show that pregabalin provides addi-
tional beneﬁt in patients with refractory NeP at a reasonable cost. To our knowledge, 
this is the ﬁrst economic model to speciﬁcally evaluate a refractory NeP population.
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OBJECTIVES: To determine if adherence to interferons used to treat patients with 
Multiple Sclerosis (MS) impacts the utilization of health care resources. METHODS: 
A retrospective cohort study design was used. Pharmacy and medical claims data for 
MS patients were extracted for 2006–2008. Adherence was measured using two 
methods for Medication Possession Ratio (MPR), one that incorporates persistence 
and one that does not. Patients were classiﬁed as adherent if they met a standard cut-
off point. The number of hospitalizations, ER visits, and physician ofﬁce visits were 
measured for each patient year. A series of regression models were used to assess the 
impact of adherence on the utilization of health care resources. RESULTS: A total of 
3590 patients were included in the study. Based on the two MPR methods, compliance 
ranged from 77.6% to 89.8%. Patient adherence is a signiﬁcant predictor of whether 
patients have at least 1 ER visit, with those who are adherent having a lower risk of 
ER visits. Patients considered adherent had a signiﬁcantly lower risk of being admitted 
to the hospital than those considered non-adherent. Adherent patients were at higher 
risk of having at least 2 physician ofﬁce visits. The full descriptive and inferential sta-
tistics, and individual year data will be included in the presentation. CONCLUSIONS: 
Interferon therapy is considered an effective treatment for MS patients. This study 
demonstrates that patient adherence to interferon therapy is important in reducing the 
use of expensive, acute health care resources. Patients who were adherent to the 
interferon therapy were less likely to have at least 1 ER visit and at least 1 hospitaliza-
tion, and more likely to have at least 2 physician ofﬁce visits. Reducing health care 
resource use can reduce the total cost of care for MS patients, and as well as increase 
an individual’s long term productivity in society.
